SCHEMBL632380

SCHEMBL632380

CC(C)(C)C1(F)CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18969629 0.97
SCHEMBL2400421 0.94
SCHEMBL18717715 0.90
SCHEMBL14946387 0.83
SCHEMBL19625802 0.75
SCHEMBL23344730 0.73
SCHEMBL10513859 0.73
SCHEMBL1847666 0.71
SCHEMBL15491810 0.71
SCHEMBL23344719 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102497888-B Perfluoro compounds for use in imaging KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) 2014-10-29 CN claimed
EP-1037619-A2 SELECTED C 10? PERFLUORINATED HYDROCARBONS FOR LIQUID VENTILATION AND ARTIFICIAL BLOOD SYNTHETIC BLOOD INTERNATIONAL, INC. (US) 2000-09-27 EP claimed
WO-1999026604-A2 SELECTED C10 PERFLUORINATED HYDROCARBONS FOR LIQUID VENTILATION AND ARTIFICIAL BLOOD SYNTHETIC BLOOD INTERNATIONAL, INC. (US) 1999-06-03 WO claimed
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-07-06 US disclosed
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE HALIA THERAPEUTICS INC (US) 2023-06-15 US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 US disclosed
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 US disclosed
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2023-05-04 US disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 US disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 US disclosed
US-20160243237-A1 EMULSIONS OF PERFLUOROCARBONS TENAX THERAPEUTICS, INC. (US) 2016-08-25 US disclosed
US-20100144597-A1 Novel combinatorial approaches to enhancing oxygen transport to tissues VIRGINIA COMMONWEALTH UNIVERSITY 2010-06-10 US disclosed
US-20100144861-A1 Perfluorocarbon gel formulations TENAX THERAPEUTICS, INC 2010-06-10 US disclosed
WO-2010033187-A1 DEEP IMMERSION FLOTATION THERAPY FOR BURN VICTIMS OXYGEN BIOTHERAPEUTICS, INC. (US) 2010-03-25 WO disclosed
WO-2010008594-A1 METHOD OF TREATING TRAUMATIC BRAIN INJURY OXYGEN BIOTHERAPEUTICS, INC. (US) 2010-01-21 WO disclosed
WO-2009102487-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS OXYGEN BIOTHERAPEUTICS, INC. (US) 2009-08-20 WO disclosed
US-20090202617-A1 Gas based wound and tissue therapeutics TENAX THERAPEUTICS, INC 2009-08-13 US disclosed
US-6167887-B1 PERFLUOROALKYL(S)-SUBSTITUTED PERFLUOROCYCLOHEXANE AND -PENTANE USED AS BIOLOGICAL GAS EXCHANGE MEDIUM IN LIQUID VENTILATION AND ARTIFICIAL BLOOD; PROPER VAPOR PRESSURE SO DOESN'T CAUSE HYPERINFLATED LUNG SYNDROME; PURE SINGLE ISOMER SYNTHETIC BLOOD INTERNATIONAL, INC. 2001-01-02 US disclosed
EP-1037619-A2 SELECTED C 10? PERFLUORINATED HYDROCARBONS FOR LIQUID VENTILATION AND ARTIFICIAL BLOOD SYNTHETIC BLOOD INTERNATIONAL, INC. (US) 2000-09-27 EP disclosed
WO-1999026604-A2 SELECTED C10 PERFLUORINATED HYDROCARBONS FOR LIQUID VENTILATION AND ARTIFICIAL BLOOD SYNTHETIC BLOOD INTERNATIONAL, INC. (US) 1999-06-03 WO disclosed